Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory…
NCT00007956 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00007956 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma |
| Official title | A Phase I Study Of Therapy With Mono-dgA-RFB4 In Patients With Relapsed And Refractory CD22+ B-Cell Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | monoclonal antibody mono-dgA-RFB4 |
| Start date | Nov 1, 2000 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: